The prices of several cancer medicines in India have fallen by more than 50% following the government’s latest drug pricing policy. However, the overall reduction across all 643 medicines listed by the National Pharmaceutical Pricing Authority (NPPA) was only around 14%, according to a recent report.
The findings show that the price reductions have not benefited all medicines equally. While some cancer treatments have become much cheaper, many other medicines continue to remain expensive. This highlights the challenges faced by the government in making essential medicines affordable for everyone.
According to the analysis, generic medicines and biosimilar drugs recorded some of the biggest price reductions. These medicines are generally more affordable alternatives to expensive branded treatments. The reduction in their prices could help patients save money, especially those who need long-term cancer treatment.
However, several expensive branded medicines did not experience similar price cuts. Medicines produced by only one manufacturer also showed limited changes in their prices. This is because there may be fewer alternatives available in the market, making it difficult to bring prices down through competition.
The report also points out that although some cancer patients may now benefit from lower treatment costs, others still have to spend large amounts on medicines. The difference in price reductions shows that government pricing measures have not affected every category of medicine in the same way.
The NPPA plays an important role in monitoring medicine prices and ensuring that essential drugs remain affordable. The latest findings have raised questions about whether the existing pricing policy is sufficient to control the cost of expensive treatments.
The analysis highlights the need for further measures to improve medicine affordability in India. Better price monitoring, increased availability of affordable alternatives and greater competition among manufacturers could help reduce the financial burden on patients.
Although the latest policy has brought significant price reductions for certain cancer medicines, the overall figures show that more efforts are needed to make expensive treatments accessible to a larger number of people.